Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands

Yuan Luo, Sheetal Vali, Suya Sun, Xuesong Chen, Xia Liang, Tatiana Drozhzhina, Elena Popugaeva, Ilya Bezprozvanny

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common form of dementia and currently affects 5.4 million Americans. A number of anti-Aβ (beta amyloid) therapeutic agents have been developed for AD, but so far all of them failed in clinic. Here we used peptoid chemistry to develop ligands selective for Aβ42. Peptoids are N-substituted glycine oligomers, a class of peptidomimics. We synthesized an on-bead peptoid library consisting of 38 416 unique peptoids. The generated peptoid library was screened and arrays of Aβ42-selective peptoid ligands were identified. One of those peptoid ligands, IAM1 (inhibitor of amyloid), and the dimeric form (IAM1)2 were synthesized and evaluated in a variety of biochemical assays. We discovered that IAM1 selectively binds to Aβ42, while the dimeric derivative (IAM1)2 has a higher affinity for Aβ42. Furthermore, we demonstrated that IAM1 and (IAM1)2 were able to inhibit the aggregation of Aβ42 in a concentration-dependent manner, and that (IAM1)2 protected primary hippocampal neurons from the Aβ-induced toxicity in vitro. These results suggest that IAM1 and (IAM1)2 are specific Aβ42 ligands with antiaggregation and neuroprotective properties. IAM1, (IAM1)2, and their derivatives hold promise as Aβ42 detection agents and as lead compounds for the development of AD therapeutic agents.

Original languageEnglish (US)
Pages (from-to)952-962
Number of pages11
JournalACS Chemical Neuroscience
Volume4
Issue number6
DOIs
StatePublished - Jun 19 2013

Fingerprint

Peptoids
Amyloid
Agglomeration
Ligands
Alzheimer Disease
N-substituted Glycines
Lead compounds
Derivatives
Oligomers
Neurons
Toxicity
Dementia
Assays

Keywords

  • Alzheimer's disease
  • beta-amyloid peptide (42&40)
  • hippocampal neurons
  • peptoids
  • scyllo-inositol

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Physiology
  • Cognitive Neuroscience
  • Medicine(all)

Cite this

Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands. / Luo, Yuan; Vali, Sheetal; Sun, Suya; Chen, Xuesong; Liang, Xia; Drozhzhina, Tatiana; Popugaeva, Elena; Bezprozvanny, Ilya.

In: ACS Chemical Neuroscience, Vol. 4, No. 6, 19.06.2013, p. 952-962.

Research output: Contribution to journalArticle

Luo, Y, Vali, S, Sun, S, Chen, X, Liang, X, Drozhzhina, T, Popugaeva, E & Bezprozvanny, I 2013, 'Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands', ACS Chemical Neuroscience, vol. 4, no. 6, pp. 952-962. https://doi.org/10.1021/cn400011f
Luo, Yuan ; Vali, Sheetal ; Sun, Suya ; Chen, Xuesong ; Liang, Xia ; Drozhzhina, Tatiana ; Popugaeva, Elena ; Bezprozvanny, Ilya. / Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands. In: ACS Chemical Neuroscience. 2013 ; Vol. 4, No. 6. pp. 952-962.
@article{89d524b163664d8c8e80974df3ee1480,
title = "Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands",
abstract = "Alzheimer's disease (AD) is the most common form of dementia and currently affects 5.4 million Americans. A number of anti-Aβ (beta amyloid) therapeutic agents have been developed for AD, but so far all of them failed in clinic. Here we used peptoid chemistry to develop ligands selective for Aβ42. Peptoids are N-substituted glycine oligomers, a class of peptidomimics. We synthesized an on-bead peptoid library consisting of 38 416 unique peptoids. The generated peptoid library was screened and arrays of Aβ42-selective peptoid ligands were identified. One of those peptoid ligands, IAM1 (inhibitor of amyloid), and the dimeric form (IAM1)2 were synthesized and evaluated in a variety of biochemical assays. We discovered that IAM1 selectively binds to Aβ42, while the dimeric derivative (IAM1)2 has a higher affinity for Aβ42. Furthermore, we demonstrated that IAM1 and (IAM1)2 were able to inhibit the aggregation of Aβ42 in a concentration-dependent manner, and that (IAM1)2 protected primary hippocampal neurons from the Aβ-induced toxicity in vitro. These results suggest that IAM1 and (IAM1)2 are specific Aβ42 ligands with antiaggregation and neuroprotective properties. IAM1, (IAM1)2, and their derivatives hold promise as Aβ42 detection agents and as lead compounds for the development of AD therapeutic agents.",
keywords = "Alzheimer's disease, beta-amyloid peptide (42&40), hippocampal neurons, peptoids, scyllo-inositol",
author = "Yuan Luo and Sheetal Vali and Suya Sun and Xuesong Chen and Xia Liang and Tatiana Drozhzhina and Elena Popugaeva and Ilya Bezprozvanny",
year = "2013",
month = "6",
day = "19",
doi = "10.1021/cn400011f",
language = "English (US)",
volume = "4",
pages = "952--962",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands

AU - Luo, Yuan

AU - Vali, Sheetal

AU - Sun, Suya

AU - Chen, Xuesong

AU - Liang, Xia

AU - Drozhzhina, Tatiana

AU - Popugaeva, Elena

AU - Bezprozvanny, Ilya

PY - 2013/6/19

Y1 - 2013/6/19

N2 - Alzheimer's disease (AD) is the most common form of dementia and currently affects 5.4 million Americans. A number of anti-Aβ (beta amyloid) therapeutic agents have been developed for AD, but so far all of them failed in clinic. Here we used peptoid chemistry to develop ligands selective for Aβ42. Peptoids are N-substituted glycine oligomers, a class of peptidomimics. We synthesized an on-bead peptoid library consisting of 38 416 unique peptoids. The generated peptoid library was screened and arrays of Aβ42-selective peptoid ligands were identified. One of those peptoid ligands, IAM1 (inhibitor of amyloid), and the dimeric form (IAM1)2 were synthesized and evaluated in a variety of biochemical assays. We discovered that IAM1 selectively binds to Aβ42, while the dimeric derivative (IAM1)2 has a higher affinity for Aβ42. Furthermore, we demonstrated that IAM1 and (IAM1)2 were able to inhibit the aggregation of Aβ42 in a concentration-dependent manner, and that (IAM1)2 protected primary hippocampal neurons from the Aβ-induced toxicity in vitro. These results suggest that IAM1 and (IAM1)2 are specific Aβ42 ligands with antiaggregation and neuroprotective properties. IAM1, (IAM1)2, and their derivatives hold promise as Aβ42 detection agents and as lead compounds for the development of AD therapeutic agents.

AB - Alzheimer's disease (AD) is the most common form of dementia and currently affects 5.4 million Americans. A number of anti-Aβ (beta amyloid) therapeutic agents have been developed for AD, but so far all of them failed in clinic. Here we used peptoid chemistry to develop ligands selective for Aβ42. Peptoids are N-substituted glycine oligomers, a class of peptidomimics. We synthesized an on-bead peptoid library consisting of 38 416 unique peptoids. The generated peptoid library was screened and arrays of Aβ42-selective peptoid ligands were identified. One of those peptoid ligands, IAM1 (inhibitor of amyloid), and the dimeric form (IAM1)2 were synthesized and evaluated in a variety of biochemical assays. We discovered that IAM1 selectively binds to Aβ42, while the dimeric derivative (IAM1)2 has a higher affinity for Aβ42. Furthermore, we demonstrated that IAM1 and (IAM1)2 were able to inhibit the aggregation of Aβ42 in a concentration-dependent manner, and that (IAM1)2 protected primary hippocampal neurons from the Aβ-induced toxicity in vitro. These results suggest that IAM1 and (IAM1)2 are specific Aβ42 ligands with antiaggregation and neuroprotective properties. IAM1, (IAM1)2, and their derivatives hold promise as Aβ42 detection agents and as lead compounds for the development of AD therapeutic agents.

KW - Alzheimer's disease

KW - beta-amyloid peptide (42&40)

KW - hippocampal neurons

KW - peptoids

KW - scyllo-inositol

UR - http://www.scopus.com/inward/record.url?scp=84879772906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879772906&partnerID=8YFLogxK

U2 - 10.1021/cn400011f

DO - 10.1021/cn400011f

M3 - Article

VL - 4

SP - 952

EP - 962

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 6

ER -